Scancell Holdings Plc · LSE:SCLP
Scancell — LSX Inv€$tival Showcase 2018
20 slides from Scancell's conference presentation, Nov 13, 2018
Slide 1: A New Frontier in Immuno-Oncology
A NEW FRONTIER IN IMMUNO-ONCOLOGY LSX Inv€$tival Showcase London, 13th November 2018 LSE: SCLP.L A NEW FRONTIER IN IMMUNO-ONCOLOGY
Slide 2: Disclaimer
DISCLAIMER The information contained in these slides has been prepared by Scancell Holdings plc (the "Company"). It has not been approved by the United Kingdom Financial Conduct Authority under the Prospectus Rules (made under Part VI of the Financial Services and Markets Act 2000) or otherwise, or
Slide 3: Differentiated Immuno-Oncology Clinical Stage Opportunity
DIFFERENTIATED IMMUNO-ONCOLOGY CLINICAL STAGE OPPORTUNITY COMPANY • Scancell is developing innovative immunotherapies for the treatment of cancer FOCUS MARKET • Immuno-oncology is one of the fastest growing sectors in the biopharmaceutical industry (est. CAGR OPPORTUNITY ~20% over next 5 years) • No
Slide 4: Meeting the Need for Effective Therapeutic Cancer Vaccines
MEETING THE NEED FOR EFFECTIVE THERAPEUTIC CANCER VACCINES Key challenge is to stimulate an effective T cell response to reject or kill the growing tumour Most vaccine strategies only stimulate low frequency, low avidity T cell responses that fail to control tumour growth Scancell’s novel ther
Slide 5: Development Pipeline
DEVELOPMENT PIPELINE IMMUNOBODY® MODITOPE® SCIB1: Targets malignant melanoma. Phase 1/2 study completed with strong Modi-1: Manufacturing process development initiated. Phase 1/2 trial in survival data. Phase 2 combination trial with immune checkpoint inhibitor TNBC, ovarian and sarcoma planned
Slide 6: The Moditope Platform
THE MODITOPE® PLATFORM Stress-Induced Post-translational Modifications (siPTM) ► One such modification involves the process of CITRULLINATION Modi-1 ► The alteration of proteins due to enzymatic conversion of arginine residues to citrulline ► Citrullination occurs as a result of a degradation and ‘r
Slide 7: Moditope Lead Candidate: Modi-1
MODITOPE® LEAD CANDIDATE: Modi-1 Modi-1 Consists of: Two citrullinated vimentin peptides (Vim-1 and Vim-2) One citrullinated enolase peptide (Eno-1) Vimentin and enolase targets are highly expressed in triple negative breast cancer (TNBC) (90%), ovarian cancer (95%), and sarcoma (100%) - all
Slide 8: Modi-1 First in Human Study
Modi-1 FIRST IN HUMAN STUDY PATIENT POPULATION ► Patients with tumours with high vimentin or enolase expression (e.g., sarcoma, triple negative breast cancer, ovarian) ► Failed or intolerant to standard of care therapies EXPANSION PHASE n Sarcoma DOSE ESCALATION Dosing regime n Dose escalation: 10,
Slide 9: Moditope TCR Research Collaboration
MODITOPE® TCR RESEARCH COLLABORATION T cells infused ADVANTAGES OF CITRULLINATED & into cancer HOMOCITRULLINATED ANTIGEN-SPECIFIC TCRS patient Citrullinated & homocitrullinated antigens are expressed by a wide range of tumours Citrullinated & homocitrullinated antigen-specific T cells recognise
Slide 10: Moditope Milestones
MODITOPE MILESTONES EXTERNAL VALIDATION OF MODITOPE® PLATFORM INTERNAL PROJECTS ADVANCED AND EXPANDED MODITOPE® Research collaboration to develop T-cell based therapies established with BioNTech License agreed with ISA Pharmaceuticals for development of Amplivant® Modi-1 conjugate therapy GMP
Slide 11: The ImmunoBody Platform
THE IMMUNOBODY® PLATFORM Proprietary patent protected platform Several cancer associated T cell epitopes are engineered into a human antibody framework to make a genetic antigen/antibody complex Delivered as a DNA plasmid using electroporation SCIB DNA Cancer antigen sequences Vector inserted
Slide 12: SCIB1 in Patients with Melanoma
SCIB1 IN PATIENTS WITH MELANOMA SCIB1 has an excellent safety profile with no dose-limiting SURVIVAL IN RESECTED PATIENTS toxicities and no serious adverse events related to study drug or delivery device Overall survival with SCIB1 treatment superior to historical survival rates TUMOUR RESPONSE
Slide 13: SCIB1 in Melanoma Patients
SCIB1 IN MELANOMA PATIENTS PATIENTS WITHOUT TUMOUR PRESENT AT STUDY ENTRY Study entry 5 years Disease-free patients Patients with recurrence Deceased patients SCIB1 dose (2/4 mg) Disease recurrence Death Surgery Radiotherapy Electrochemotherapy Ipilimumab Nivolumab Pembrolizumab -60 -50 -40 -30 -20
Slide 14: SCIB1 Boosts Immune Checkpoint Therapy
SCIB1 BOOSTS IMMUNE CHECKPOINT THERAPY IN A MOUSE MELANOMA MODEL, SURVIVAL RATES WERE SIGNIFICANTLY BOOSTED WHEN ANTI-PD-1 THERAPY WAS COMBINED WITH SCIB1 TREATMENT Survival rates for SCIB1 ImmunoBody® monotherapy ≈ anti-PD-1 Monotherapy viable option for resected melanoma patients Combination
Slide 15: SCIB1 + Checkpoint Inhibitor Combination Phase 2 Trial
SCIB1 + CHECKPOINT INHIBITOR COMBINATION PHASE 2 TRIAL PATIENT POPULATION Histologically confirmed, unresectable AJCC stage III or stage IV melanoma No prior systemic treatment for advanced disease Suitable for treatment with Keytruda (pembrolizumab), with measurable disease Part 1 safety ru
Slide 16: Identified Opportunities in a Range of Treatment Settings
IDENTIFIED OPPORTUNITIES IN A RANGE OF TREATMENT SETTINGS IMMUNOBODY® MODITOPE® SCIB1 Modi-1 & Modi-2 In combination with checkpoint inhibitors in patients with late stage disease to increase efficacy without siPTM vaccine class compromising safety As monotherapy in patients with resected dise
Slide 17: Highlights for FY17/18
HIGHLIGHTS FOR FY17/18 Operational Financial SCIB2 clinical development partnership with Cancer Cash at bank on 30th April 2018 was £10,303,168 (2017: Research UK (CRUK)-December 2017 £2,672.335) Moditope research Collaboration with BioNTech to develop T- Overall loss for the year £4,194,509
Slide 18: Anticipated Newsflow + Milestones CY19
ANTICIPATED NEWSFLOW + MILESTONES CY19 IMMUNOBODY® MODITOPE® SCIB1 Modi-1 SCIB1/checkpoint inhibitor Phase 2 US/UK Preparation for the First-In-Human study with Modi-1 combination study in late stage melanoma, planned to in patients with TNBC, ovarian cancer and sarcoma start 1H19, subject to re
Slide 19: Future Value Drivers
FUTURE VALUE DRIVERS 2 PLATFORMS, 4 LEAD PRODUCTS + 5 CORE ACTIVITIES • Generate meaningful clinical data to address unmet needs: clinical read-outs (SCIB1 CLINICAL DATA Phase 2 & Modi-1 Phase1/2 pt 1) anticipated in next 2 years • Extend utility of Moditope platform beyond Modi-1 and Modi-2 in asso
Slide 20: Contact
Contact Dr. Cliff Holloway, CEO Email: cliffholloway@scancell.co.uk A NEW FRONTIER IN IMMUNO-ONCOLOGY 20 20